0
0
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial - BioSpace
2/21/23 at 10:12am
Organization
BioSpace
Author
BioSpace
57 words
0
Comments
Amydis Inc. announced initiation of enrollment of patients with cerebral amyloid angiopathy, an age-associated disease in which a protein called amyloid beta builds up on the walls of the arteries in the brain increasing the risk for stroke and dementia.
You are the first to view
https://www.biospace.com/article/releases/amydis-announces-enrollment-of-cerebral-amyloid-angiopathy-participants-in-phase-1-2a-retinal-tracer-trial/
Create an account or login to join the discussion